STAA
STAAR Surgical Company NASDAQ$27.29
Mkt Cap $1.4B
52w Low $15.59
76.9% of range
52w High $30.81
50d MA $21.17
200d MA $23.44
P/E (TTM)
-16.8x
EV/EBITDA
-28.4x
P/B
3.9x
Debt/Equity
0.1x
ROE
-23.4%
P/FCF
-29.2x
RSI (14)
—
ATR (14)
—
Beta
1.04
50d MA
$21.17
200d MA
$23.44
Avg Volume
1.3M
About
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats fa…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | AMC | 0.18 | -0.20 | -211.1% | 18.92 | -6.6% | +1.6% | -1.8% | -2.4% | -3.2% | -8.9% | +6.8% | — |
| Nov 5, 2025 | AMC | 0.18 | 0.46 | +155.6% | 25.25 | +0.4% | +5.5% | +5.1% | +8.6% | +8.5% | +2.4% | +0.5% | — |
| Aug 6, 2025 | AMC | -0.56 | -0.07 | +87.5% | 26.90 | +0.0% | +0.2% | +1.3% | +1.5% | +1.8% | +4.9% | +3.9% | — |
| May 7, 2025 | AMC | -0.59 | -0.52 | +11.9% | 19.44 | -5.9% | +0.5% | -0.1% | +4.3% | -2.3% | -10.3% | -8.1% | — |
| Feb 11, 2025 | AMC | 0.02 | -0.50 | -2600.0% | 21.88 | -33.7% | -24.7% | -27.1% | -29.8% | -24.0% | -18.8% | -20.4% | — |
| Oct 30, 2024 | AMC | 0.19 | 0.37 | +94.7% | 29.49 | +6.2% | -1.7% | -3.2% | -1.2% | +1.8% | +4.6% | -1.3% | — |
| Aug 7, 2024 | AMC | 0.25 | 0.33 | +32.0% | 36.35 | +12.0% | +11.0% | +5.6% | +6.0% | +1.0% | -3.4% | -14.4% | — |
| May 7, 2024 | AMC | 0.05 | 0.06 | +20.0% | 46.65 | -3.5% | -12.1% | -8.1% | -9.2% | -6.6% | -6.4% | -13.2% | — |
| Feb 26, 2024 | AMC | 0.19 | 0.24 | +26.3% | 31.75 | +3.9% | +2.9% | -0.6% | -1.6% | +4.9% | +8.7% | +18.7% | — |
| Nov 1, 2023 | AMC | 0.20 | 0.30 | +50.0% | 43.32 | -10.4% | -16.9% | -12.7% | -20.4% | -19.3% | -22.0% | -23.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | Wedbush | Maintains | Neutral → Neutral | — | $20.88 | $24.85 | +19.0% | +20.7% | +26.6% | +28.5% | +17.0% | +18.4% |
| Apr 9 | Canaccord Genuity | Upgrade | Hold → Buy | — | $20.88 | $24.85 | +19.0% | +20.7% | +26.6% | +28.5% | +17.0% | +18.4% |
| Mar 5 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $19.22 | $18.93 | -1.5% | -3.4% | -4.0% | -4.7% | -10.4% | -8.1% |
| Mar 4 | Stifel | Maintains | Hold → Hold | — | $18.92 | $17.67 | -6.6% | +1.6% | -1.8% | -2.4% | -3.2% | -8.9% |
| Feb 9 | Stifel | Maintains | Hold → Hold | — | $17.58 | $17.47 | -0.6% | -1.0% | -1.6% | -1.9% | -6.2% | -8.4% |
| Jan 28 | Jefferies | Maintains | Buy → Buy | — | $19.04 | $18.94 | -0.5% | +0.6% | -0.5% | -0.5% | -5.3% | -4.7% |
| Jan 16 | Canaccord Genuity | Maintains | Hold → Hold | — | $20.97 | $20.53 | -2.1% | +0.0% | +0.0% | -1.7% | -5.2% | -8.7% |
| Dec 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $25.39 | $23.63 | -6.9% | -5.5% | -2.8% | -5.0% | -7.2% | -2.3% |
| Dec 10 | Canaccord Genuity | Maintains | Hold → Hold | — | $25.39 | $23.63 | -6.9% | -5.5% | -2.8% | -5.0% | -7.2% | -2.3% |
| Aug 7 | Stifel | Downgrade | Buy → Hold | — | $26.90 | $26.90 | +0.0% | +0.2% | +1.3% | +1.5% | +1.8% | +4.9% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
STAAR's Q1 2026 net sales expected to exceed $90 million, more than doubling year-over-year, signaling strong demand for its eye surgery products and justifying a significant upward stock revaluation.
Apr 8
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Without seeing the actual press release content in Exhibit 99.1, I cannot provide specific stock impact analysis, as the "transition described above" is not included in your summary.
Please share the full filing details or the press release text for accurate assessment.
Mar 24
8-K · 7.01
! Medium
Staar Surgical Co -- 8-K 7.01: Regulation FD Disclosure
Staar Surgical will hold a conference call on March 3, 2026 to discuss Q4 and full-year 2025 financial results with interim co-CEOs presenting operational and financial performance.
Mar 3
8-K · 5.02
!!! Very High
Staar Surgical Co -- 8-K 5.02: Executive Change
STAAR Surgical's Chief Legal Officer Nathaniel Sisitsky terminated employment effective February 4, 2026, requiring investors to monitor leadership transition implications and potential interim management arrangements.
Feb 5
8-K · 5.02
!!! Very High
Staar Surgical Co -- 8-K 5.02: Executive Change
Staar Surgical appoints Warren Foust as CEO effective February 1, 2026, promoting the CFO to Vice President, signaling leadership transition that may affect operational strategy and investor confidence.
Feb 2
Data updated apr 27, 2026 3:04am
· Source: massive.com